Glaukos competitors

John Francis Crowley (born April 7, 1967) is an American biotechnology executive and entrepreneur and the chairman and CEO of Amicus Therapeutics. He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, and founded Orexigen Therapeutics. In 2006, he was profiled in the book The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children by Geeta Anand. In 2010, Crowley released his memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy. Crowley and his family were the inspiration for the movie Extraordinary Measures starring Harrison Ford and Brendan Fraser in 2010.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.

Mr. Carmel serves as Chief Executive Officer and director of CannaPowder (PINK: CAPD), a bio-pharma company dedicated to developing and applying innovative technology in the cannabinoid field. Mr. Carmel also serves as a director of Chiron Refineries Ltd. (TASE: CHR), a company engaged in consulting and initiation of transactions in the refineries field. In addition he serves as chairman of the Israel Tennis Table Association. He also served as vice president business development at Yaad Givatayim development, a municipal corporation dedicated to initiate, develop and establish projects of public importance. Prior to Yaad Givatayim, Mr. Carmel served as an investment manager and as a research and strategy analyst at Excellence Nessuah, one of the leading companies in the field of provident and advanced studies funds in Israel.

Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System. Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm. At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

Mr. Michael Hooven D. is a President and Chief Executive Officer at Enable Injections and is based in United States.